Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner ...

H.C. Wainwright has maintained its Neutral rating and $7.00 price target for Kyverna Therapeutics Inc (NASDAQ: KYTX) following the company's recent presentation at the European ...

Kyverna Therapeutics, Inc. (KYTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

NASDAQ KYTX opened at $3.03 on Thursday. Kyverna Therapeutics has a 1-year low of $2.64 and a 1-year high of $30.60. The business has a 50 day simple moving average of $3.63 and a two-hundred day ...

Kyverna Therapeutics, Inc. (KYTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

Kyverna Therapeutics has a fifty-two week low of $2.91 and a fifty-two week high of $30.60. The firm’s fifty day moving average is $3.79 and its 200 day moving average is $5.31. Institutional ...

This page features the latest news about the Kyverna Therapeutics stock. KYTX stock touches 52-week low at $2.78 amid sharp annual decline Kyverna Therapeutics Inc. (KYTX) stock has reached a new ...

On Monday, Morgan Stanley initiated coverage on Kyverna Therapeutics Inc (NASDAQ:KYTX), a biopharmaceutical company, with an Overweight rating and a price target of $40.00. The... Monday - Kyverna ...